{"id":"W2984927918","doi":"10.1200/jco.19.00172","title":"Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":772,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); Seagen (Canada); Jewish General Hospital; Spinal Cord Injury BC; University of British Columbia","funders":"TG Therapeutics; H. Lundbeck A/S; BeiGene; Pharmacyclics; Genentech; Exelixis; Karyopharm Therapeutics; MEI Pharma; Astex Pharmaceuticals; F. Hoffmann-La Roche; Teva Pharmaceutical Industries; Kite Pharma; National Cancer Institute; Gilead Sciences; Sanofi; MorphoSys; Celgene; American Society of Clinical Oncology; Bristol-Myers Squibb; AstraZeneca; Spectrum Pharmaceuticals; Amgen; Pfizer; GlaxoSmithKline","keywords":"Medicine; Internal medicine; Bendamustine; Rituximab; Neutropenia; Hazard ratio; Cohort; Diffuse large B-cell lymphoma; Transplantation; Gastroenterology; Surgery; Oncology; Lymphoma; Chemotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001293659,0.0002178113,0.0007331857,0.0001926627,0.0001459527,0.0004526691,0.0002781442,0.0002471787,0.0004241261],"category_scores_gemma":[0.0009430264,0.00009288197,0.0003357406,0.0002328364,0.0002930684,0.0001986549,0.0001550928,0.0005208002,0.0001202396],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004945997,"about_ca_system_score_gemma":0.000395394,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004562024,"about_ca_topic_score_gemma":0.001443696,"domain_scores_codex":[0.9995403,0.0002677256,0.00004183988,0.00005594477,0.00005274083,0.000041378],"domain_scores_gemma":[0.9994443,0.0001968406,0.000164421,0.00003311968,0.00003213672,0.0001290864],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1374824,0.003871606,0.1587627,0.002105262,0.001293905,0.001729475,0.0005044761,0.004303407,0.06665336,0.0005120575,0.003799687,0.6189817],"study_design_scores_gemma":[0.07956077,0.3075383,0.5356939,0.0005874876,0.002502127,0.008715892,0.0004104879,0.009651008,0.02143825,0.001348534,0.0324843,0.00006897086],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9814051,0.01652863,0.0003050161,0.0002365345,0.00005031808,0.0001403483,0.0001390995,0.00002913729,0.001165886],"genre_scores_gemma":[0.9970744,0.002213553,0.0001871562,0.0001879984,0.00003738714,0.0000342254,0.0001069573,0.00000306118,0.0001553744],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001293659,"threshold_uncertainty_score":0.0068416,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06801833353446632,"score_gpt":0.4233675724693748,"score_spread":0.3553492389349084,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}